IZOTROPIC CORP. (1R3) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IZOTROPIC CORP. (1R3) has a cash flow conversion efficiency ratio of 0.029x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-157.22K ≈ $-183.81K USD) by net assets (€-5.34 Million ≈ $-6.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IZOTROPIC CORP. - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how IZOTROPIC CORP.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 1R3 current and long-term liabilities for a breakdown of total debt and financial obligations.
IZOTROPIC CORP. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IZOTROPIC CORP. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Medadvisor Ltd
AU:MDR
|
5.093x |
|
Check-Cap Ltd
F:7CC
|
2.441x |
|
Euroland Corporate SA
PA:MLERO
|
N/A |
|
Together Startup Network Ltd
TA:TGTR
|
-0.149x |
|
Agro Yasa Lestari PT Tbk
JK:AYLS
|
-0.001x |
|
HYDROTOR SA
WAR:HDR
|
0.017x |
|
Meta Epsi Tbk PT
JK:MTPS
|
0.244x |
|
Wahana Pronatural
JK:WAPO
|
0.002x |
Annual Cash Flow Conversion Efficiency for IZOTROPIC CORP. (2022–2025)
The table below shows the annual cash flow conversion efficiency of IZOTROPIC CORP. from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see market value of IZOTROPIC CORP..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | €-4.86 Million ≈ $-5.68 Million |
€-636.23K ≈ $-743.82K |
0.131x | -15.15% |
| 2024-04-30 | €-3.85 Million ≈ $-4.50 Million |
€-593.57K ≈ $-693.95K |
0.154x | -85.48% |
| 2023-04-30 | €-3.07 Million ≈ $-3.59 Million |
€-3.27 Million ≈ $-3.82 Million |
1.063x | -91.64% |
| 2022-04-30 | €-374.59K ≈ $-437.93K |
€-4.76 Million ≈ $-5.57 Million |
12.718x | -- |
About IZOTROPIC CORP.
Izotropic Corporation, a research and development company, develops diagnostic products for detecting breast cancers. The company develops and commercializes IzoView, a CT diagnostic imaging device with a platform of targeted uses offering high resolution, true 3D dedicated breast imaging with 360-degree image acquisition and can be used with or without injectable contrast. Izotropic Corporation … Read more